Micromet Buys Out MedImmune’s Remaining Rights to Blinatumomab

10-Nov-2009 - USA

Micromet, Inc. announced that it has signed an agreement with MedImmune, LLC to buy out MedImmune’s rights to blinatumomab in North America, and to terminate the collaboration agreement signed in 2003 under which MedImmune had been granted the right to develop and commericalize blinatumomab in North America. As a result of this transaction, Micromet now controls global rights to develop and commercialize blinatumomab.

In March 2009, MedImmune returned the North American rights to develop and commercialize blinatumumab to Micromet, but retained an option to reacquire the right to commercialize blinatumomab in North America. Under the terms of the termination agreement, Micromet has now regained MedImmune’s remaining rights relating to blinatumomab as well as any other BiTE antibodies binding to antigens relevant for hematological cancers that had been reserved for MedImmune under the terminated agreement. Micromet will make upfront, milestone, and royalty payments to MedImmune related to the development and North American net sales of blinatumomab.

“The advancement of blinatumomab in the clinic is the top priority for Micromet,” said Micromet CEO Christian Itin. “With complete control over global development and commercialization of blinatumomab, Micromet can develop an integrated clinical and regulatory strategy across multiple commercial territories, starting with the first pivotal study that we expect to initiate in 2010.”

Blinatumomab is a therapeutic antibody that activates a patient's T cells to seek out and destroy lymphoma and leukemia cells.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous